Poon Christine A 的 Form 4 申報
Regeneron Pharmaceuticals, Inc.REGN，2026/11/4 申報
- 申報編號
- 0001189014-26-000009
- 申報時間
- 2026/11/4 16:09 ET
- 交易日
- 2026/11/2
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 7 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $758.8 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Poon Christine ACIK 0001189014 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/2 | Common Stock | M行使選擇權取得 | +7,830 | $376.69 | +$2,949,482.7 | 13,049 | 直接 | |
| 2026/11/2 | Common Stock | S賣出處分 | −218 | $966.74F1 | −$210,749.32 | 12,831 | 直接 | |
| 2026/11/2 | Common Stock | S賣出處分 | −772 | $967.38F2 | −$746,817.36 | 12,059 | 直接 | |
| 2026/11/2 | Common Stock | S賣出處分 | −2,499 | $968.58F3 | −$2,420,481.42 | 9,560 | 直接 | |
| 2026/11/2 | Common Stock | S賣出處分 | −3,203 | $969.50F4 | −$3,105,308.5 | 6,357 | 直接 | |
| 2026/11/2 | Common Stock | S賣出處分 | −937 | $970.51F5 | −$909,367.87 | 5,420 | 直接 | |
| 2026/11/2 | Common Stock | S賣出處分 | −201 | $971.31F6 | −$195,233.31 | 5,219 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/2 | Common Stock | M行使選擇權處分 | −7,830 | $0.00 | $0 | 0 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents volume-weighted average price of sales of 218 shares of Company stock on November 2, 2026 at prices ranging from $966.39 to $966.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F2
Represents volume-weighted average price of sales of 772 shares of Company stock on November 2, 2026 at prices ranging from $967.06 to $967.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Represents volume-weighted average price of sales of 2,499 shares of Company stock on November 2, 2026 at prices ranging from $968.00 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents volume-weighted average price of sales of 3,203 shares of Company stock on November 2, 2026 at prices ranging from $969.01 to $969.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents volume-weighted average price of sales of 937 shares of Company stock on November 2, 2026 at prices ranging from $970.00 to $970.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F6
Represents volume-weighted average price of sales of 201 shares of Company stock on November 2, 2026 at prices ranging from $971.16 to $971.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。